Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Clinical Oncology

• Publication date

  2006-10-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2006.07.1316PMID 17050876
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

  2007cited by this paper
• Gefitinib-sensitizing mutations in esophageal carcinoma.

  2006cited by this paper
• Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.

  2006cited by this paper
• Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction

  2005cited by this paper
• Radiation therapy and tamoxifen: concurrent or sequential? That is the question.

  2005cited by this paper
• Approval Summary for Erlotinib for Treatment of Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer after Failure of at Least One Prior Chemotherapy Regimen

  2005cited by this paper
• Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer.

  2005cited by this paper
• Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.

  2005cited by this paper
• Epidemiology of esophageal adenocarcinoma

  2005cited by this paper
• Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

  2005cited by this paper
• Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

  2005cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Gefitinib phase II study in second-line treatment of advanced esophageal cancer

  2004cited by this paper
• Phase II trial of gefitinib (ZD1839) in advanced adenocarcinoma of the oesophagus incorporating biopsy before and after gefitinib

  2004cited by this paper
• Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

  2004cited by this paper
• Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).

  2002cited by this paper
• Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.

  2001cited by this paper
• Estimating the world cancer burden: Globocan 2000

  2001cited by this paper
• The EGF receptor family as targets for cancer therapy

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors

  2000cited by this paper
• New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

  2000cited by this paper
• The changing epidemiology of esophageal cancer.

  1999cited by this paper
• Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

  1997cited by this paper
• Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.

  1997cited by this paper
• Epidermal growth factor-related peptides and their receptors in human malignancies.

  1995cited by this paper

• Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects.

  2024cites this paper
• Circular RNA CircSLC22A23 Promotes Gastric Cancer Progression by Activating HNRNPU Expression

  2024cites this paper
• Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies

  2024cites this paper
• Characterization of gastric cancer-stimulated signaling pathways and function of CTGF in cancer-associated fibroblasts

  2024cites this paper
• BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C‐MYC/PLCG1/Perk Axis

  2023cites this paper
• Exploring the chemotherapeutic potential of currently used kinase inhibitors: An update

  2023cites this paper
• Molecularly Targeted Therapies for Gastric Cancer. State of the Art

  2021cites this paper
• The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review

  2021cites this paper
• Early TP53 Alterations Shape Gastric and Esophageal Cancer Development

  2021cites this paper
• Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma

  2020cites this paper
• Emerging precision therapies for gastric cancer

  2020cites this paper
• Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

  2020cites this paper
• Targeted therapies for gastroesophageal cancers

  2020cites this paper
• Current Molecular Targeted Agents for Advanced Gastric Cancer

  2020cites this paper
• Recent Advancements in Biomarkers and Early Detection of Gastrointestinal Cancers

  2020cites this paper
• Gastric Cancer: Role of Phytochemicals and Tyrosine Kinase Inhibitors

  2020cites this paper
• Phytochemicals Targeting Tumor Microenvironment in Gastrointestinal Cancers

  2020cites this paper
• Genetic Marker Identification for the Detection of Early-Onset Gastric Cancer Through Genome-Wide Association Studies

  2020cites this paper
• Gastric Cancer Heterogeneity and Clinical Outcomes

  2020influential citation
• Deregulated expression of Elastin Microfibril Interfacer 2 (EMILIN2) in gastric cancer affects tumor growth and angiogenesis

  2020cites this paper
• OTT_A_246412 4075..4088

  2020cites this paper
• Nanoformulations of Small Molecule Protein Tyrosine Kinases Inhibitors Potentiate Targeted Cancer Therapy.

  2020cites this paper
• Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

  2019cites this paper
• The human epidermal receptors in gastric cancer: molecular alterations and its role as therapeutic targets

  2019cites this paper
• Gastric Cancers

  2019cites this paper
• Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer

  2019cites this paper
• Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies

  2019cites this paper
• From Molecular Classification to Targeted Therapy for Gastric Cancer in the Precision Medicine Era

  2019cites this paper
• Cancer Management by Tyrosine Kinase Inhibitors: Efficacy, Limitation, and Future Strategies

  2019cites this paper
• Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer

  2019cites this paper
• Next-generation sequencing and biomarkers for gastric cancer: what is the future?

  2019cites this paper
• Current therapeutic landscape for advanced gastroesophageal cancers.

  2018cites this paper
• Loss of Multimerin-2 and EMILIN-2 Expression in Gastric Cancer Associate with Altered Angiogenesis

  2018cites this paper
• Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines

  2018cites this paper
• Drug Resistance Against Tyrosine Kinase Inhibitor in Gastrointestinal Malignancies

  2018cites this paper
• Proposed Molecular and miRNA Classification of Gastric Cancer

  2018cites this paper
• Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.

  2018cites this paper
• Advances in molecular, genetic and immune signatures of gastric cancer: Are we ready to apply them in our patients’ decision making?

  2018cites this paper
• The Clinical and Biological Significance of Tyrosine Kinases in Gastric Cancer

  2018cites this paper
• Efficacy and Safety of Erlotinib Addition to Concurrent Chemoradiation in Patients of Unresectable Esophageal Carcinoma: a Comparative Study

  2018cites this paper
• DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells

  2018cites this paper
• Lapatinib in combination with paclitaxel plays synergistic antitumor effects on esophageal squamous cancer

  2018cites this paper
• Co-operative groups in the development of chemotherapy for gastric cancer.

  2018cites this paper
• Factores predictores del grado de regresión tumoral en los tumores gástricos localmente avanzados

  2018cites this paper
• Beclin1 antagonizes LAPTM4B-mediated EGFR overactivation in gastric cancer cells.

  2017cites this paper
• Advanced gastric adenocarcinoma: optimizing therapy options

  2017cites this paper
• miR-455 inhibits cell proliferation and migration via negative regulation of EGFR in human gastric cancer.

  2017cites this paper
• Novel Targeted Therapies for Esophagogastric Cancer.

  2017cites this paper
• Targeted Therapy in the Management of Advanced Gastric Cancer: Are We Making Progress in the Era of Personalized Medicine?

  2017cites this paper
• The c-Met receptor: Implication for targeted therapies in colorectal cancer

  2017cites this paper
• Rôle de la GTPase ARF1 dans la migration et l’invasion des cellules du cancer du sein

  2017cites this paper
• 7 Current Therapy for Esophageal Adenocarcinoma

  2017cites this paper
• Update on Gastroesophageal Adenocarcinoma Targeted Therapies.

  2017cites this paper
• Comparative study of radiotherapy plus erlotinib versus chemoradiotherapy for elderly patients with esophageal cancer: a propensity score-matched analysis.

  2017cites this paper
• Durable and Complete Response to Herceptin Monotherapy in Patients with Metastatic Gastroesophageal Cancer

  2017cites this paper
• Targeted Therapy in Advanced Gastric Cancer

  2017cites this paper
• Gastric cancer management: Kinases as a target therapy

  2017cites this paper
• Unresectable and Metastatic Cancer

  2017cites this paper
• Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations

  2017cites this paper
• Predictive biomarkers along gastric cancer pathogenetic pathways

  2017cites this paper
• New agents on the horizon in gastric cancer

  2017cites this paper
• n er Prognostic biom arkers in upper gastrointestinal adenocarcinom a 125 Prognostic biomarkers in upper gastrointestinal adenocarcinoma

  2017cites this paper
• Palliative Chemotherapie: Standard und Individualisierung des Magen- und Kardiakarzinoms

  2017cites this paper
• Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer

  2017cites this paper
• Angiogenesis inhibitors in early development for gastric cancer

  2017cites this paper
• MicroRNA-509-3p Inhibits Cancer Cell Proliferation and Migration via Upregulation of XIAP in Gastric Cancer Cells

  2017cites this paper
• Epstein – Barr virus-associated gastric cancer

  2017cites this paper
• Systemic therapy for esophagogastric cancer: targeted therapies.

  2017cites this paper
• Molecular Prognostic Factors in Gastric Cancer

  2017cites this paper
• Overexpression of EGFR as an Independent Prognostic Factor in Adenocarcinoma of the Esophagogastric Junction.

  2017cites this paper
• Epidermal growth factor receptor inhibition downregulates Helicobacter pylori-induced epithelial inflammatory responses, DNA damage and gastric carcinogenesis

  2017cites this paper
• Molecular targeted therapy for the treatment of gastric cancer

  2016cites this paper
• Improving Outcomes in Resectable Gastric Cancer: A Review of Current and Future Strategies.

  2016cites this paper
• Clinical impact of tumour biology in the management of gastroesophageal cancer

  2016cites this paper
• Esophageal cancer: comparative effectiveness of treatment options

  2016cites this paper
• Targeted Treatment of Esophagogastric Cancer

  2016cites this paper
• Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines

  2016influential citation
• Molecular profiles in foregut oncology.

  2016cites this paper
• Molecular-targeted first-line therapy for advanced gastric cancer.

  2016cites this paper
• Gastric biomarkers: a global review

  2016cites this paper
• Silencing of FGFR4 could influence the biological features of gastric cancer cells and its therapeutic value in gastric cancer

  2016cites this paper
• Novel targets in the treatment of advanced gastric cancer: a perspective review

  2016cites this paper
• OncoBinder facilitates interpretation of proteomic interaction data by capturing coactivation pairs in cancer

  2016cites this paper
• Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?

  2016cites this paper
• Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine.

  2016cites this paper
• Personalised Treatment in Gastric Cancer: Myth or Reality?

  2016cites this paper
• Personalized medicine in gastric cancer: Where are we and where are we going?

  2016cites this paper
• Beyond HER2: recent advances and future directions in targeted therapies in esophagogastric cancers.

  2016cites this paper
• Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma

  2016influential citation
• Resistance to Tyrosine Kinase Inhibitors in Different Types of Solid Cancer

  2016cites this paper
• New advances in targeted gastric cancer treatment.

  2016cites this paper
• Heterogeneity in gastric cancer and the impact on patient survival

  2016cites this paper
• Current advances in targeted therapies for metastatic gastric cancer: improving patient care.

  2016cites this paper
• Systemic Treatment of Esophageal Cancer

  2016cites this paper
• Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma.

  2016cites this paper
• Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer.

  2016cites this paper
• EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma.

  2016cites this paper
• Translating gastric cancer genomics into targeted therapies.

  2016cites this paper
• The over-expression of FGFR4 could influence the features of gastric cancer cells and inhibit the efficacy of PD173074 and 5-fluorouracil towards gastric cancer

  2016cites this paper
• Biomarkers and novel agents in esophago-gastric cancer: are we making progress?

  2015cites this paper